It is possible that prolonged treatment with a single-agent MET inhibitor in patients could lead to changes in the tumor or the tumor microenvironment, including changes in growth factor expression, necessitating treatment with a combination of an EGFR and MET inhibitor, although we did not observe this to be the case in the course of our studies. The gene discussed is MET; the disease is neoplasm.